Hemostasis variables in type I diabetic patients without demonstrable vascular complications
- PMID: 8375244
- DOI: 10.2337/diacare.16.8.1137
Hemostasis variables in type I diabetic patients without demonstrable vascular complications
Abstract
Objective: To determine hemostasis variables in type I diabetic patients without clinically demonstrable micro- and macroangiopathy and to relate them to glycemic control.
Research design and methods: Fifty patients and 50 comparable control subjects were enrolled in this study. The patients were subdivided in two groups, according to their level of HbA1c (group 1, n = 30, HbA1c < or = 8%; group 2, n = 20, HbA1c > 8%). We determined the platelet count, the platelet aggregation in the spontaneous state and in the presence of ADP or collagen, beta-thromboglobulin, platelet factor 4, fibrinogen, von Willebrand factor (factors VIII:C, VIIIR:Ag, and VIIIR:VW), plasma and urinary fibrinopeptide A, euglobulin lysis time, anticoagulant proteins C and S, and plasma viscosity.
Results: All coagulation variables were significantly higher in diabetic patients compared with control subjects. Moreover, when the patients were subdivided according to their levels of HbA1c, the hemostatic disturbances appeared significantly more pronounced in the poorly controlled than in the well-controlled subjects.
Conclusions: This study confirms the existence of a state of hypercoagulability in type I diabetes. This hypercoagulability may be related to poor glycemic control. Our study suggests that the hemostasis disturbances precede demonstrable vascular complications.
Similar articles
-
Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus.Diabetes Care. 1984 Mar-Apr;7(2):174-9. doi: 10.2337/diacare.7.2.174. Diabetes Care. 1984. PMID: 6203689
-
Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study.Diabetologia. 1997 Jun;40(6):698-705. doi: 10.1007/s001250050736. Diabetologia. 1997. PMID: 9222650
-
Platelet function in male diabetics with and without macrovascular complications.Diabetes Res Clin Pract. 1992 Feb;15(2):143-8. doi: 10.1016/0168-8227(92)90018-m. Diabetes Res Clin Pract. 1992. PMID: 1563330
-
[Some parameters of hemostasis and fibrinolysis in diabetic patients].Pol Arch Med Wewn. 1998 Aug;100(2):133-8. Pol Arch Med Wewn. 1998. PMID: 10101928 Clinical Trial. Polish.
-
Time course of changes in in vitro platelet function and plasma von willebrand factor activity (VIIIR:WF) and factor VIII-related antigen (VIIIR:Ag) in the diabetic rat.J Lab Clin Med. 1983 Nov;102(5):795-804. J Lab Clin Med. 1983. PMID: 6415193
Cited by
-
Renal functional reserve in patients with Type 1 diabetes mellitus.Wien Klin Wochenschr. 2004 Apr 30;116(7-8):246-51. doi: 10.1007/BF03041055. Wien Klin Wochenschr. 2004. PMID: 15143864
-
Fibrinolytic activity in Nigerian diabetics.Postgrad Med J. 2004 Oct;80(948):610-2. doi: 10.1136/pgmj.2003.017996. Postgrad Med J. 2004. PMID: 15466998 Free PMC article. Clinical Trial.
-
Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.Clin Res Cardiol. 2023 Nov;112(11):1517-1528. doi: 10.1007/s00392-022-02080-5. Epub 2022 Aug 17. Clin Res Cardiol. 2023. PMID: 35976428 Free PMC article.
-
Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.Am Heart J. 2019 Aug;214:158-166. doi: 10.1016/j.ahj.2019.05.003. Epub 2019 May 10. Am Heart J. 2019. PMID: 31212115 Free PMC article.
-
Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials.Curr Diab Rep. 2012 Jun;12(3):294-304. doi: 10.1007/s11892-012-0272-9. Curr Diab Rep. 2012. PMID: 22528594 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical